Azitra Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Branford, Connecticut and currently employs 12 full-time employees. The company went IPO on 2023-06-16. Azitra, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
Follow-Up Questions
Azitra Inc 'in CEO'su kimdir?
Mr. Francisco Salva 2021 'den beri şirketle birlikte olan Azitra Inc 'in President 'ıdır.
AZTR hissesinin fiyat performansı nasıl?
AZTR 'in mevcut fiyatı $0.76 'dir, son işlem günde 0.39% increased etti.
Azitra Inc için ana iş temaları veya sektörler nelerdir?
Azitra Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Azitra Inc 'in piyasa değerlemesi nedir?
Azitra Inc 'in mevcut piyasa değerlemesi $2.6M 'dir
Azitra Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 4 analist Azitra Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir